Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a privately held biotechnology company headquartered in London, UK. The acquisition brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), both respiratory viruses, and expands the capabilities in vaccine design and development with Vicebio’s ‘Molecular Clamp’ technology..

赛诺菲今天宣布已达成协议，收购总部位于英国伦敦的私营生物技术公司Vicebio Ltd（“Vicebio”）。此次收购引入了一种针对呼吸道合胞病毒（RSV）和人类偏肺病毒（hMPV）的早期联合疫苗候选物，这两种病毒均为呼吸道病毒，并通过Vicebio的“分子钳”技术扩展了疫苗设计与开发的能力。

The vaccine candidate complements Sanofi’s position in the respiratory vaccines space where the company is present in flu and RSV prevention. It allows Sanofi to offer increased physician and patient choice in RSV and hMPV by adding a non-mRNA vaccine to its pipeline.

该候选疫苗补充了赛诺菲在呼吸道疫苗领域的地位，该公司在流感和RSV预防方面已有布局。通过在其研发管线中增加一款非mRNA疫苗，赛诺菲能够为RSV和hMPV提供更多的医生和患者选择。

In addition, the acquisition adds ‘Molecular Clamp’, an innovative technology that stabilizes viral proteins in their native shape, enabling the immune system to recognize and respond to them more effectively. This approach enables quicker development of fully liquid combination vaccines that can be stored at standard refrigeration temperatures (2–8°C), eliminating the need for freezing or freeze-drying, thereby simplifying manufacturing and distribution.

此外，此次收购还增加了“分子钳”这一创新技术，该技术能够将病毒蛋白稳定在其天然形状，使免疫系统能够更有效地识别和应对它们。这种方法可以更快地开发出完全液态的组合疫苗，这些疫苗可以在标准冷藏温度（2-8°C）下储存，无需冷冻或冻干，从而简化了生产和分发流程。

Furthermore, fully liquid vaccines can be made available in prefilled syringes, enhancing ease of use, safety, and operational efficiency across healthcare settings. .

此外，全液态疫苗可以以预填充注射器的形式提供，提高在各种医疗环境中的使用便利性、安全性和操作效率。

'Vicebio's ‘Molecular Clamp’ technology introduces a purposefully simple but thoughtful

Vicebio的“分子夹”技术引入了一种刻意简单但经过深思熟虑的

approach to further improve vaccine designs at a time when respiratory viral infections continue to impact millions globally”

“在呼吸道病毒感染持续影响全球数百万人的时候，进一步改进疫苗设计的方法”

, said

，说道

Jean-François Toussaint

让-弗朗索瓦·图森

, Global Head of Research and Development Vaccines at Sanofi. “

赛诺菲全球研发疫苗部门负责人。“

This acquisition furthers Sanofi's dedication to vaccine innovation with the potential to develop next-generation combination vaccines that could provide protection to older adults against multiple respiratory viruses with a single immunization.'

此项收购进一步体现了赛诺菲对疫苗创新的承诺，有望开发出下一代组合疫苗，为老年人提供针对多种呼吸道病毒的单一免疫保护。

“We are excited to join Sanofi”,

“我们很高兴加入赛诺菲”，

Emmanuel Hanon

埃马纽埃尔·哈农

, Chief Executive Officer at Vicebio.

Vicebio首席执行官。

“Their global scale and deep expertise in vaccine development provide the ideal environment to fully realize the potential of our innovative technology. As part of the Sanofi team, we look forward to advancing our platform and pipeline to deliver meaningful benefits for patients and public health.”.

“他们在疫苗开发方面具有全球规模和深厚的专业知识，这为充分实现我们创新技术的潜力提供了理想的环境。作为赛诺菲团队的一员，我们期待推进我们的平台和管道，为患者和公共卫生带来有意义的好处。”

Vicebio’s pipeline includes VXB-241, a bivalent vaccine candidate targeting RSV and hMPV, currently in an exploratory phase 1 study in older adults, and VXB-251, a preclinical trivalent vaccine candidate targeting RSV, hMPV and parainfluenza virus Type 3 (PIV3). RSV, HMPV and PIV3 are leading causes of lower respiratory tract infections such as pneumonia.

Vicebio的研发管线包括VXB-241，一种针对RSV和hMPV的双价疫苗候选药物，目前正在进行老年人群中的探索性1期研究，以及VXB-251，一种临床前阶段的三价疫苗候选药物，靶向RSV、hMPV和副流感病毒3型（PIV3）。RSV、HMPV和PIV3是导致下呼吸道感染（如肺炎）的主要原因。

While often causing overlapping symptoms such as cough, fever, and respiratory distress, these viruses are antigenically distinct, frequently co-circulating and contributing to seasonal surges in respiratory illness that can lead to older adult frailty, hospitalization and, in some cases, death..

尽管这些病毒常常引起咳嗽、发烧和呼吸困难等重叠症状，但它们在抗原上是不同的，经常共同传播，导致呼吸道疾病在季节性激增，可能引起老年人衰弱、住院，甚至在某些情况下导致死亡。

Financial considerations

财务考虑因素

Under the terms of the agreement, Sanofi would acquire all of Vicebio’s share capital for a total upfront payment of $1,15 billion, with potential milestone payments of up to $450 million based on development and regulatory achievements. The transaction is expected to close in Q4 2025, subject to customary closing conditions, including receipt of regulatory approvals.

根据协议条款，赛诺菲将收购Vicebio的全部股本，总预付款为11.5亿美元，并可能基于开发和监管成果追加高达4.5亿美元的里程碑付款。该交易预计将在2025年第四季度完成，但需满足惯例成交条件，包括获得监管机构的批准。

The acquisition will not have a significant impact on Sanofi’s financial guidance for 2025..

此次收购不会对赛诺菲2025年的财务指引产生重大影响。

About Sanofi

关于赛诺菲

Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.

赛诺菲是一家以研发为驱动、以人工智能为助力的生物制药公司，致力于改善人们的生活并实现令人瞩目的增长。我们凭借对免疫系统的深刻理解，开发出能够治疗和保护全球数百万人的药物和疫苗，并通过创新的研发管线使数百万人进一步受益。我们的团队秉承一个使命：追逐科学奇迹以改善人们的生活；这激励我们通过应对当今最紧迫的医疗、环境和社会挑战，推动进步并为我们服务的人群和社区带来积极影响。

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.

赛诺菲在 EURONEXT（欧元区股票交易所）的代码为 SAN，在 NASDAQ（纳斯达克）的代码为 SNY。

About Vicebio

关于Vicebio

Vicebio is focused on developing next-generation respiratory virus vaccines using the Molecular Clamp Technology. The company was founded with investment from Medicxi and acquired the rights to the Molecular Clamp technology through a license from UniQuest, the commercialization arm of The University of Queensland, Australia.

Vicebio 专注于使用分子钳技术开发下一代呼吸道病毒疫苗。该公司由 Medicxi 投资成立，并通过从澳大利亚昆士兰大学的商业化部门 UniQuest 获得的许可，取得了分子钳技术的使用权。

This proprietary technology was developed by Prof. Paul Young, Prof. Daniel Watterson, and Prof. Keith Chappell at UQ. For more information, please visit: .

这项专有技术由昆士兰大学的保罗·杨教授、丹尼尔·瓦特森教授和基思·查佩尔教授开发。欲了解更多信息，请访问：。